| Literature DB >> 23872293 |
Lloyd Einsiedel1, Liselle Fernandes, Sheela Joseph, Alex Brown, Richard J Woodman.
Abstract
OBJECTIVES: We hypothesise that rising prevalence rates of non-communicable diseases (NCDs) increase infection risk and worsen outcomes among socially disadvantaged Indigenous Australians undergoing a rapid epidemiological transition.Entities:
Keywords: Infectious Diseases; Microbiology
Year: 2013 PMID: 23872293 PMCID: PMC3717469 DOI: 10.1136/bmjopen-2013-003070
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Demographics and comorbidities for indigenous and non-indigenous BSI patients 2003–2007
| Indigenous (n=558) | Non-indigenous (n=55) | p Value for difference | |
|---|---|---|---|
| Age (years) (±SD) | 44.7±15.2 | 57.5±21.1 | <0.001 |
| Gender (M/F) (%) | 234/324 (42/58) | 31/23 (57/43) | 0.03 |
| Residence | |||
| Urban | 89 (16.0) | 55 (100.0) | |
| Town camp | 136 (24.4) | 0 (0.0) | |
| Remote community | 333 (59.7) | 0 (0.0) | <0.001 |
| Comorbidities* | |||
| Diabetes | 247 (44.3) | 11 (20.0) | <0.001 |
| Harmful alcohol consumption | 205 (37.0) | 7 (12.7) | <0.001 |
| Chronic kidney disease | |||
| Stages 3–4 | 34 (6.1) | 5 (9.1) | 0.39 |
| Stage 5 | 83 (14.9) | 3 (5.5) | 0.06 |
| Chronic liver disease† | 53 (9.6) | 6 (10.9) | 0.74 |
| Bronchiectasis | 27 (4.8) | 0 | 0.10 |
| Congestive cardiac failure | 15 (2.7) | 3 (5.5) | 0.25 |
| Ischaemic heart disease | 9 (1.6) | 7 (15.2) | <0.001 |
| Valvular heart disease | 27 (4.8) | 3 (5.5) | 0.84 |
| Rheumatic heart disease | 12 (2.0) | 0 (0.0) | 0.27 |
| Palliative care | 10 (1.8) | 5 (9.1) | 0.001 |
| Malignancy | 13 (2.3) | 11 (20.0) | <0.001 |
| IVDU | 0 (0.0) | 3 (5.5) | 0.001 |
| Community acquired | 510 (91.6) | 49 (90.7) | 0.84 |
| Primary focus of BSI | |||
| No focus | 250 (44.8) | 20 (36.4) | 0.37 |
| Pneumonia‡ | 110 (19.7) | 6 (10.9) | 0.08 |
| Skin abscess | 66 (11.8) | 5 (9.1) | 0.65 |
| Pyelonephritis§ | 63 (11.3) | 5 (9.1) | 0.56 |
| Other | 53 (9.5) | 18 (32.7) | <0.001 |
| Enteritis | 15 (2.7) | 1 (1.8) | 0.71 |
| Bone/joint | 1 (0.2) | 0.0 (0.0) | 0.61 |
| Additional infections¶ | |||
| Acute bacterial infections | 69 (12.4) | 2 (3.6) | 0.05 |
| Pneumonia | 18 (3.2) | 0 (0.0) | 0.39 |
| Urinary tract infection | 20 (3.6) | 1 (1.8) | 0.49 |
| Skin infection | 27 (4.8) | 1 (1.8) | 0.31 |
| Enteritis | 4 (0.7) | 0 | 0.53 |
| Chronic viral infections | |||
| HTLV-1** | 137 (45.2) | 0 (0.0) | <0.001 |
| Hepatitis B virus** | |||
| HBsAg | 49 (12.9) | 1 (6.7) | 0.70 |
| Anti-HBc | 193 (62.5) | 3 (27.3) | <0.001 |
| Parasites | |||
| Strongyloidiasis** | 78 (36.1) | 0 (0.0) | 0.001 |
| Scabies | 20 (4.0) | 0 (0.0) | 0.24 |
| Mortality | |||
| 28 days | 62 (11.1) | 7 (12.7) | 0.72 |
| All deaths | 145 (26.0) | 15 (27.3) | 0.84 |
| Age of death (years) | 47±15 | 68±21 | <0.001 |
| Major BSI pathogens†† | 1029 | 110 | |
| 370 (36.0) | 38 (34.5) | 0.56 | |
| 246 (66.5) | 28 (73.7) | 0.37 | |
| 57 (15.4) | 2 (5.3) | 0.09 | |
| | 191 (18.6) | 20 (18.2) | 0.83 |
| MRSA | 53 (27.8) | 1 (5.0) | <0.001 |
| | 136 (13.2) | 8 (5.9) | <0.001 |
| | 68 (6.6) | 8 (7.3) | 0.42 |
| 22 (2.14) | 0 | 0.14 | |
| Enteric pathogens‡‡ | 29 (2.81) | 1 (0.91) | 0.27 |
*Comorbidities determined from ICD-10 AM discharge morbidity codes.
†Chronic liver disease attributed to alcohol (Indigenous, 43; non-Indigenous, 5), chronic hepatitis B (Indigenous, 10; non-Indigenous, 0) and chronic hepatitis C (Indigenous, 0; non-Indigenous, 3).
‡Chest X-rays performed for 457 Indigenous patients. Respiratory cultures performed for 150 Indigenous patients.
§Urine cultures performed for 310 Indigenous patients.
¶Pathogens identified in addition to those isolated from blood cultures. Pneumonia, urinary tract, skin and enteritis expressed as a proportion of the total number of acute bacterial infections.
**Indigenous patients tested: HTLV-1, 309; HBsAg, 388; HBcAb, 309; Strongyloides stercoralis serology, 235. Non-Indigenous patients tested: HTLV-1, 4; HBsAg, 16; HBcAb, 11; Strongyloides stercoralis serology, 4. Denominators exclude six Indigenous patients with indeterminate HTLV-1 western blot results and 19 Indigenous patients with borderline Strongyloides serology whose infective status could not be determined.
††Major BSI pathogens for all recorded episodes 2001–2007. E coli and K pneumoniae expressed as a proportion of the Enterobacteriaceae and MRSA expressed as a proportion of all S aureus isolates.
‡‡Includes Salmonella spp., Shigella spp., Campylobacter spp.
BSI, bloodstream infection; HBsAg, hepatitis B surface antigen positive; anti-HBc, Hepatitis B core antibody positive; HTLV-1, human T-lymphotropic virus type 1; ICD, International Classification of Diseases; IVDU, intravenous drug use; MRSA, methicillin-resistant Staphylococcus aureus.
Figure 1Bloodstream infection incidence rates according to ethnicity and place of residence. Town camp, Indigenous residents of town camp; urban, Indigenous residents of township who do not reside in a town camp; remote, Indigenous residents of remote Indigenous communities. Non-Indigenous residents of Alice Springs region.
Demographic and non-communicable disease associations for the major BSI pathogens isolated from Indigenous adults
| N | No (%) | Yes (%) | p Value* | No (%) | Yes (%) | p Value* | No (%) | Yes (%) | p Value* | No (%) | Yes (%) | p Value* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Residence | |||||||||||||
| Urban | 89 | 86.5 | 13.5 | 89.9 | 10.1 | 96.6 | 3.4 | 76.4 | 23.6 | ||||
| Town camp | 136 | 88.2 | 11.8 | 83.1 | 16.9 | 91.9 | 8.1 | 73.5 | 26.5 | ||||
| Remote | 333 | 80.5 | 19.5 | 0.08 | 89.2 | 10.8 | 0.15 | 94.6 | 5.4 | 0.30 | 73.0 | 27.0 | 0.81 |
| Diabetes | |||||||||||||
| No | 310 | 86.5 | 13.6 | 83.9 | 16.1 | 93.9 | 6.1 | 74.1 | 25.8 | ||||
| Yes | 247 | 79.8 | 20.2 | 0.035 | 92.7 | 7.3 | 0.002 | 94.7 | 5.3 | 0.66 | 72.9 | 27.1 | 0.73 |
| CRF | |||||||||||||
| No | 524 | 83.4 | 16.6 | 87.6 | 12.4 | 94.3 | 5.7 | 73.7 | 26.3 | ||||
| Yes | 34 | 82.4 | 17.7 | 0.87 | 91.2 | 8.8 | 0.54 | 94.1 | 5.9 | 0.97 | 73.5 | 26.5 | 0.99 |
| HD | |||||||||||||
| No | 475 | 84.2 | 15.8 | 86.3 | 13.7 | 94.1 | 5.9 | 70.5 | 29.5 | ||||
| Yes | 83 | 78.3 | 21.7 | 0.18 | 96.4 | 3.6 | 0.01 | 95.2 | 4.8 | 0.70 | 92.6 | 8.4 | <0.001 |
| CLD | |||||||||||||
| No | 505 | 82.4 | 17.6 | 87.7 | 12.3 | 93.9 | 6.1 | 73.5 | 26.5 | ||||
| Yes | 53 | 92.5 | 7.6 | 0.06 | 88.7 | 11.3 | 0.84 | 98.1 | 1.9 | 0.20 | 75.6 | 24.5 | 0.75 |
| Alcohol | |||||||||||||
| No | 349 | 82.2 | 17.8 | 92.0 | 8.0 | 95.1 | 4.9 | 75.1 | 24.9 | ||||
| Yes | 205 | 84.9 | 15.1 | 0.42 | 80.5 | 19.5 | <0.001 | 93.1 | 6.8 | 0.33 | 71.7 | 28.3 | 0.38 |
*Using chi-squared test of association.
Major BSI pathogens recorded during the final BSI admission.
Alcohol, harmful alcohol consumption; BSI, bloodstream infection; CRF, stage 3 or 4 chronic renal disease; HD, stage 5 renal disease; CLD, chronic liver disease.
Infections recorded for Indigenous and non-Indigenous adults during the 5 years prior to the final BSI presentation*
| Indigenous n=431 (%) | Non-Indigenous (n=52) | p Value | |
|---|---|---|---|
| Any | 296 (68.7) | 18 (34.6) | <0.001 |
| BSI | 105 (24.4) | 4 (7.7) | 0.007 |
| Respiratory tract | 179 (41.5) | 3 (5.8) | <0.001 |
| Pneumonia | 164 (38.1) | 4 (7.7) | <0.001 |
| >3 Episodes | 32 (7.4) | 0 (0.0) | 0.04 |
| Exacerbation BE | 13 (6.0) | 0 (0.0) | 0.20 |
| Skin/soft tissue infections | 154 (35.7) | 7 (13.5) | 0.001 |
| Abscess | 88 (20.5) | 0 (0.0) | <0.001 |
| Cellulitis | 47 (10.9) | 7 (13.7) | 0.55 |
| Wound infection | 42 (9.7) | 0 (0.0) | 0.02 |
| Pyelonephritis | 77 (17.9) | 4 (7.7) | 0.06 |
| Bone/joint | 11 (2.6) | 0 (0.0) | 0.24 |
| Enteritis | 21 (4.9) | 1 (1.9) | 0.33 |
| Scabies | 14 (3.3) | 0 (0.0) | 0.19 |
| Other | 6 (1.4) | 0 (0.0) | 0.39 |
*Excluding haemodialysis patients (n=83 indigenous, 3 non-indigenous), patients with bronchiectasis (n=27 Indigenous, 0 non-indigenous) and those residing outside the Alice Springs urban and rural districts for whom data were not available (Indigenous, 18; non-Indigenous, 0).
BSI, bloodstream infections; BE, bronchiectasis.
Multivariate adjusted ORs for demographic factors and non-communicable diseases associated with previous infections among Indigenous patients*
| Any infection (n=470)† OR (95% CI) | BSI (n=553) OR (95% CI) | Skin† (n=470) OR (95% CI) | Pneumonia‡ (n=443) OR (95% CI) | |
|---|---|---|---|---|
| Residence | ||||
| Urban | 1.00 | 1.00 | 1.00 | 1.00 |
| Town camp | 1.2 (0.6 to 2.4) | 1.8 (0.9 to 3.4) | 1.3 (0.7 to 2.5) | 1.3 (0.7 to 2.6) |
| Remote | 0.8 (0.5 to 1.4) | 1.3 (0.7 to 2.3) | 1.2 (0.7 to 2.2) | 0.8 (0.4 to 1.4) |
| Age (10 years) | 0.9 (0.8 to 1.0) | 1.1 (0.9 to 1.2) | 0.9 (0.8 to 1.0) | 1.0 (0.9 to 1.2) |
| Gender (0=F, 1=M) | 1.0 (0.7 to 1.5) | 1.3 (0.9 to 1.9) | 1.0 (0.7 to 1.6) | 1.0 (0.7 to 1.6) |
| Diabetes | 1.4 (0.9 to 2.2) | 1.1 (0.7 to 1.7) | 2.1 (1.4 to 3.3) | 1.1 (0.7 to 1.7) |
| CRF | 3.0 (1.1 to 8.2) | 1.7 (0.8 to 3.8) | 1.5 (0.7 to 3.2) | 1.6 (0.7 to 3.7) |
| Alcohol | 2.8 (1.8 to 4.4) | 1.7 (1.1 to 2.5) | 1.7 (1.1 to 2.6) | 4.3 (2.8 to 6.7) |
*Previous infections during the 5 years prior to the final BSI in the study period. Adjusted for other risk factors in the table.
†Excluding patients receiving haemodialysis.
‡Excluding patients receiving haemodialysis and those with bronchiectasis.
BSI, bloodstream infections; CRF, chronic renal failure excluding patients receiving haemodialysis.
Figure 2Survival following the final BSI recorded during the study period according to the place of residence. Urban, residence within the township but not in a town camp; town camp, residence in a town camp within the township; remote, residence in a remote indigenous community. The median follow-up time for all Indigenous subjects was 3.23 years and for urban, town camp and remote subjects, it was 2.99, 3.04 and 3.38 years, respectively.
Multivariate analysis of factors associated with 28-day and long-term survival for 510 Indigenous patients following a community-acquired BSI*
| Deaths (28 days) | Deaths (all) | 28-day survival | Long-term survival | ||||
|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | p Value | HR (95% CI) | p Value | |||
| Residence | |||||||
| Urban | 63 | 7 | 20 | 1.00 | 0.12 | 1.0 | 0.28 |
| Town camp | 125 | 20 | 37 | 1.7 (0.7 to 4.1) | 1.2 (0.7 to 2.2) | ||
| Remote | 302 | 22 | 67 | 0.9 (0.4 to 2.0) | 0.9 (0.5 to 1.5) | ||
| Age (10 years) | 1.04 (0.8 to 1.3) | 0.70 | 1.0 (0.9 to 1.1) | 0.99 | |||
| Gender (0=F,1=M) | 298F/212M | 23/26 | 65/59 | 1.5 (0.8 to 2.7) | 0.17 | 1.3 (0.9 to 2.0) | 0.13 |
| CLD (0=no, 1=yes) | 41 | 11 | 20 | 3.3 (1.6 to 6.7) | 0.001 | 2.5 (1.5 to 4.2) | <0.001 |
| Non-RHD | 37 | 9 | 16 | 2.9 (1.4 to 6.2) | 0.005 | 2.1 (1.2 to 3.6) | 0.01 |
| CRF | 28 | 6 | 11 | 2.6 (1.0 to 6.5) | 0.04 | 2.3 (1.2 to 4.3) | 0.01 |
| Malignancy | 11 | 3 | 10 | 2.9 (0.9 to 9.9) | 0.09 | 6.0 (3.0 to 12.4) | <0.001 |
| Organism† | |||||||
| 143 | 5 | 22 | 1.0 | 1.0 | |||
| 83 | 7 | 18 | 2.7 (1.0 to 7.3) | 0.05 | 1.8 (1.1 to 3.0) | 0.03 | |
| 29 | 12 | 15 | 2.3 (0.7 to 7.5) | 0.17 | 1.4 (0.7 to 2.7) | 0.17 | |
| 67 | 5 | 17 | 13.4 (4.6 to 39.2) | <0.001 | 4.8 (2.5 to 9.5) | <0.001 | |
| Other | 188 | 20 | 52 | 1.8 (0.5 to 6.3) | 0.37 | 1.5 (0.8 to 3.0) | 0.22 |
*Survival following the final BSI recorded during the study period. Analysis excludes 48 nosocomial BSI episodes.
†Pathogens isolated from the last positive blood cultures drawn during the study period.
BSI, bloodstream infection; CCF, congestive cardiac failure; CLD, chronic liver disease; CRF, chronic renal failure; non-RHD, non-rheumatic heart disease.